Sickle cell disease (SCD) is a genetic disorder caused by a single point mutation (β6 Glu→
Val) on the β-chain of adult hemoglobin (HbA) that results in sickled hemoglobin (HbS). In …

Background: Sickle cell disease (SCD) is caused by polymerization of Hemoglobin S,
resulting in red blood cell (RBC) sickling, RBC destruction, vaso-occlusive episodes and …

The pathophysiology associated with sickle cell disease (SCD) includes hemolytic anemia,
vaso-occlusive events, and ultimately end organ damage set off by the polymerization of …

Hypoxia-induced polymerization of sickle hemoglobin (Hb S) is the principal phenomenon
that underlays the pathophysiology and morbidity associated with sickle cell disease (SCD) …

We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440
(36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its …

Sickle cell disease is an inherited disorder of hemoglobin (Hb). During a sickle cell crisis,
deoxygenated sickle hemoglobin (deoxyHbS) polymerizes to form fibers in red blood cells …

Aromatic aldehydes and ethacrynic acid (ECA) exhibit antipolymerization properties that are
beneficial for sickle cell disease therapy. Based on the ECA pharmacophore and its atomic …

Sickle cell disease (SCD) is a group of inherited disorders affecting red blood cells, which is
caused by a single mutation that results in substitution of the amino acid valine for glutamic …

Candidate drugs to counter intracellular polymerization of deoxygenated sickle hemoglobin
(Hb S) continue to represent a promising approach to mitigating the primary cause of the …

Compounds that bind to sickle hemoglobin (Hb S) producing an allosteric shift to the high‐
affinity Hb S that does not polymerize are being developed to treat sickle cell anemia (SCA) …